logo

Biotech Daily Dose

Share SHARE

Pharma-112217.jpg Today's Daily Dose brings you news about FDA approval of the first 2-drug regimen for HIV; share repurchase by SunLink Health; promising early observations from DelMar's phase II trial of VAL-083 in glioblastoma; Starpharma's progress in Bacterial Vaginosis trial and Ardelyx's pipeline update.

Pharma-111717.jpg Today's Daily Dose brings you news about Aerie's progress in phase II trial of glaucoma drug in Japan; phase III results of Egalet's pain pill; FDA approval of GlaxoSmithKline's COPD drug; expanded labeling for Pfizer's kidney cancer drug Sutent and Roche's double blessing on Thursday.

pharma-111617.jpg Today's Daily Dose brings you news about FDA approval of Faslodex-Verzenio combo for advanced breast cancer; EDAP's disappointing Q3 results; upcoming clinical trial catalysts of TapImmune, and the first drug to be greenlighted for Sly syndrome.

Pharma-111517.jpg Today's Daily Dose brings you news about Apollo Medical's fiscal 2018 second quarter financial results; FDA approval of AstraZeneca's asthma drug; EyeGate's upcoming clinical trial catalysts; Genmab's revised revenue outlook and Pacira's update on its EXPAREL sNDA.

Pharma-111417.jpg Today's Daily Dose brings you news about expanded FDA approval for Allergan's schizophrenia drug; post-hoc analysis of Lilly's EMPA-REG OUTCOME trial; Court ruling against MediWound; extension of FDA's decision deadline by 3 months on Theratechnologies' biologics license application, TRACON's phase I data and Zymeworks' deal with Janssen Biotech.

Pharma-111017.jpg Today's Daily Dose brings you news about Arena's progress in phase II study of Etrasimod in ulcerative colitis; expanded FDA approval of Bristol-Myers' leukemia drug Sprycel; voluntarily delisting of Mylan's ordinary shares from the Tel Aviv Stock Exchange and Vanda's disappointment over Fanaptum's failure to win the CHMP's backing.

Pharma-111017.jpg Today's Daily Dose brings you news about the strong Q3 results of Omeros, FDA approvals of hepatitis B vaccine, CINV drug and a lymphoma drug.

Pharma-110917.jpg Today's Daily Dose brings you news about OTIC's Ménière's disease trial results; the IPO of Apellis; AEZS' upcoming milestone; Fibrogen's corporate update; CAPR's progress n HOPE program and CDTX's near-term catalyst.

Pharma-110817.jpg Today's Daily Dose brings you news about regulatory decision on Collegium's pain drug and Keryx's kidney drug; upcoming events of Xeneon, and Q3 financial results of medical technology company Inogen.

FDA-Approved-Oct-110717.jpg Yet another month has gone by, and it's time again to take a look-back at the new drugs that successfully crossed the therapeutics finish line. At the time of writing, 37 novel drugs were approved by the FDA for this year. This compares favorably with 22 novel drugs that were approved for the whole of 2016. Click here for the list of new drugs approved in October.

Pharma-110717.jpg Today's Daily Dose brings you news about FDA approval of Roche's drugs; update on the clinical hold on Cellectis' UCART123 studies; CryoLife's progress in BioGlue clinical trial in China; harrowing wait for expanded approval of Keryx's kidney drug Auryxia and Lannett's outlook.

Pharma-110317.jpg Today's Daily Dose brings you news about Alnylam's promising preliminary phase I trial results of investigational Lumasiran for the treatment of Primary Hyperoxaluria Type 1; an update on Anavex Life's ANAVEX2-73 trial results in mild-to-moderate Alzheimer's patients and Dynavax's upcoming regulatory catalyst.

Pharmacompanies-110317.jpg Shares of Arbutus Biopharma Corp. (ABUS) have gained an impressive 122% year-to-date, thanks to rising investor optimism about the Company's pipeline. Also, let's take a look at few other pharma stocks that grabbed headlines this week.

IMGN-110317.jpg Shares of ImmunoGen Inc. (IMGN) are up an impressive 160% year-to-date compared to a gain of just 17.5% by the iShares NASDAQ Biotechnology Index (IBB) during the same period.

Pharma-110217.jpg Today's Daily Dose brings you news about publication of AveXis' promising data of AVXS-101 in patients with spinal muscular atrophy Type 1 in NEJM; stellar Q3 results of Exelixis and Neurocrine, and failure of Momenta/Mylan's biosimilar drug trial.

Follow RTT